Cytomegalovirus (CMV) is thought to possess oncogenic properties and has been linked with a number of human malignancies. CMV infection was recently described in association with malignant gliomas. The intent of the present study was to further investigate the reported association between CMV and malignant gliomas. Tissue from 22 brain tumors of various histologic types and grades, four normal brains, six breast carcinomas, six colon carcinomas, six lung carcinomas, and six sarcomas were evaluated for the presence of CMV by polymerase chain reaction (PCR), in situ hybridization, and immunohistochemical methods. None of the brain tumors or normal brain tissue tested demonstrated evidence of CMV pp65 or early nuclear proteins by immunohistochemistry. In addition, no CMV RNA or DNA was detected in these cases by in situ hybridization and PCR. None of the carcinomas or sarcomas evaluated were positive for CMV by immunohistochemistry, in situ hybridization, or PCR. The findings of the present study suggest that CMV is not significantly associated with brain tumors in humans.
The etiology of primary malignant brain tumors remains largely unknown. While there is general agreement that inherited and genetic factors influence brain tumor development, the potential role of other environmental contributors remains unclear. 1, 2 Among the many suggested environmental risk factors associated with brain tumors, only exposure to ionizing radiation has been recognized as an etiologic agent in the development of brain neoplasms. 3, 4 In contrast, the role of viral infections in the evolution of brain tumors is still poorly understood.
While DNA from several types of polyoma viruses has been detected in a variable percentage of human brain tumors, [5] [6] [7] [8] [9] there has been no conclusive evidence to indicate that such viral agents directly promote tumorigenesis. Simian virus 40, a contaminant of polio vaccines utilized between 1955 and 1963, [8] [9] [10] in particular has been implicated as a causative agent in the development of neurologic malignancies, as viral sequences have been detected in brain tumors at an overall frequency of approximately 35%. [9] [10] [11] [12] However, epidemiological data have not supported a clear relationship between virus-contaminated vaccinations and an increased risk for brain tumors. 8, 10, 13 Human cytomegalovirus (CMV) possesses many oncogenic properties and has been linked to several different human malignancies.
14-17 CMV has not been well investigated in the context of malignant gliomas, but a recent report has documented the presence of CMV in a number of these tumors. 18 In this particular study, Cobbs et al 18 demonstrated immunohistochemical evidence of CMV IE1-72 protein in 27 of 27 gliomas of different histologic grades, with CMV pp65 protein also detected in a subset of these cases. CMV nucleic acids were also observed in a number of these tumors by in situ hybridization and polymerase chain reaction (PCR) methods. In contrast, CMV was not detected in tissue derived from normal brains and brains involved by non-neoplastic neurologic processes, suggesting a potential role for the virus in the pathogenesis of gliomas.
In order to further investigate the relationship between CMV and gliomas, we analyzed a series of brain tumors of various histologic types and grades for evidence of CMV infection. The presence of CMV was evaluated by determining the expression of CMV proteins by immunohistochemistry and the presence of viral genomes by in situ hybridization and PCR.
Materials and methods

Patient Samples
City of Hope National Medical Center Institutional Review Board approval was obtained for this study. The material used in this study was obtained from the files of the Department of Pathology at the City of Hope National Medical Center and consisted of 22 brain tumors, four normal brains, six breast carcinomas, six colon carcinomas, six lung carcinomas, and six sarcomas. The brain tumors were classified and graded according to World Health Organization criteria 19 and consisted of eight cases of glioblastoma (WHO grade IV), six anaplastic astrocytomas (WHO grade III), three diffuse astrocytomas (WHO grade II), two oligodendrogliomas (WHO grade II), and three ependymomas (WHO grade II). Formalinfixed paraffin-embedded tissue from each case was utilized for PCR, in situ hybridization, and immunohistochemical studies as described below.
Polymerase Chain Reaction
Total DNA was extracted from formalin-fixed, paraffin-embedded tissue sections, using 0.2 mg/ ml. of proteinase K digestion at 551C overnight, followed by denaturation by boiling. The PCR studies were performed with 2 ml of extracted DNA in a 30 ml mixture containing 50 mmol/l KCL, 10 mmol/l Tris buffer (pH 8.3), 50 mm of each deoxynucleotide triphosphate, 2.5 mmol/l MgCl 2 , 1 U of HotStarTaq DNA Polymerase (QIAGEN, Valencia, CA, USA), and 20 pmol of each primer. External and internal oligonucleotide primers specific for CMV glycoprotein B gene were utilized. 20 The external primers used were 5 0 -TCCAACACC CACAGTACCCGT-3 0 and 5 0 -CGGAAACGATGGTG TAGTTCG-3 0 and the internal primers used were 5 0 -TGACGGTCAAGGATCAGTGGC-3 0 and 5 0 -GTAAA CCACATCACCCGTGGA-3 0 . The expected amplification product size was 146 bp. After initial denaturation for 15 min at 951C, 45 amplification cycles were performed as follows: denaturing at 941C for 30 s, annealing for 30 s at 561C, and extension at 721C for 40 s. A final extension at 721C for 7 min completed the PCR amplification. The PCR setup and post-PCR work were performed in separate laboratories to minimize the possibility of contamination. Primers flanking the b-globin gene were used as a positive control for DNA preservation (expected PCR product size was 268 bp) and DNA derived from known CMV-positive colonic tissue from an immunocompromised organ transplant recipient was used as a positive control. The amplified products obtained were separated by electrophoresis on gels and visualized with ethidium bromide staining under ultraviolet light. PCR products were subsequently subjected to Southern blot analysis and hybridized with an appropriate probe (5 0 -AAGGATACTTG-GAGCGCGCAGTA-3 0 ).
In Situ Hybridization
In situ hybridization was performed using a digoxigenin-labeled 21 base oligonucleotide probe (5 0 -GTGGTGGCGCTGGGGGTGGCG-3 0 ) complementary to highly expressed CMV early gene messenger RNA (mRNA). A second probe specific for CMV DNA was also utilized, constructed from CMV pp65 21 and pp150 22 plasmids. The plasmids were digested using SalI/BamHI and BamHI/EcoRI, respectively. The inserts were run on an agarose gel and purified using a QIAEX II Extraction Kit (Qiagen, Valencia, CA, USA). The HCMV DNA probe was labeled with biotin using the Megaprime DNA Labelling System (Amersham Biosciences, Piscataway, NJ, USA).
Sections cut from formalin-fixed paraffin-embedded tissue were deparaffinized, digested with pronase, and then hybridized overnight with the digoxigenin-labeled oligonucleotide probe. Sections were then washed with 2 Â SSC, incubated with 2% normal sheep serum in 0.3% Triton in Tris-saline buffer (pH 7.5) for 30 min at room temperature, and subsequently incubated with Anti-Digoxigenin-AP, Fab fragments (1:500 dilution) (Roche Applied Science, Germany) for 2 h at room temperature. Sections were subsequently washed for 3 min in Tris-saline buffer, incubated in McGadey's substrate at 371C for 1 h, briefly washed in distilled water, air dried, and coverslipped. No counterstain was used. A poly d(T) was used as a control for total RNA preservation as described elsewhere. 23 In situ hybridization utilizing the CMV DNA probe was performed in a similar fashion. Following application of the probe to deparaffinized and digested tissue sections, the sections were denatured at 921C for 10 min and then hybridized overnight at 371C. Detection was performed using avidin alkaline phosphatase conjugate and McGadey's substrate. CMV-positive colonic tissue from an immunocompromised organ transplant recipient was used as a positive control.
Immunohistochemistry
Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded sections using the following monoclonal antibodies: anti-CMV (clones CCH2 and DDG9, dilution 1:200, DAKO, Carpinteria, CA, USA), which is a cocktail of two antibodies that react with a 76 kDa HCMV early protein and the delayed early DNA binding protein p52, and anti-pp65 (clones 2 and 6, dilution 1:50, Novocastra, Newcastle upon Tyne, UK), which is specific for CMV pp65 protein. Slides were pretreated by proteolytic digestion with proteinase K (DAKO) for 5 min (anti-CMV) or by steam heating slides in citrate buffer (pH 6.0) in a steamer (Black and Decker, Shelton, CT, USA) for 20 min (antipp65). Staining was performed using an automated immunostainer (DAKO), followed by antibody detection using the DAKO EnVision þ System and 3,3
0 -diaminobenzidine as a chromogen. The slides were counterstained with hematoxylin and coverslipped. Sections of known CMV-positive colonic tissue from an immunocompromised organ transplant recipient were used as a positive control.
Results
The results of the CMV studies are summarized in Table 1 . All astrocytic, oligodendroglial, and ependymal tumors of the brain examined demonstrated no evidence of CMV proteins by immunohistochemistry utilizing anti-CMV and anti-pp65 antibodies. Samples of normal brain were likewise immunohistochemically negative for CMV proteins. Using an oligonucleotide probe specific for CMV early gene mRNA, positive signals indicative of CMV mRNA were identified in positive control tissue, but not in any of the brain tumors and normal brain tissues analyzed by in situ hybridization. All cases studied exhibited strong positivity for poly d(T), indicating adequate RNA preservation. In addition, in situ hybridization was also performed using a probe for CMV DNA, which similarly detected no CMV nucleic acids in the neoplastic and normal brain tissues studied. Each case was further analyzed for the presence of CMV DNA by PCR. The primers utilized amplified a band of the appropriate size from the positive control tissue; however, none of the brain neoplasms or non-neoplastic brain tissues examined yielded a PCR product indicative of CMV DNA (Figure 1a) . Strong b-globin amplified bands were identified by PCR from all cases, indicating adequate DNA present (Figure 1b) . All carcinomas of the breast, lung, and colon, as well as each of the sarcomas studied were negative for CMV by immunohistochemistry, in situ hybridization, and PCR methods.
Discussion
CMV is a widely distributed herpesvirus associated with a broad spectrum of clinical diseases. The virus is capable of establishing persistent and latent infections that are usually asymptomatic, but can cause significant disease in neonates and immunosuppressed individuals. CMV has also been viewed as a potential oncogenic virus. In vitro studies have demonstrated the ability of whole virus and viral DNA fragments to transform mammalian cells morphologically. [14] [15] [16] [17] In addition, CMV infection has been shown to stimulate nucleic acid and protein synthesis, activate transcription of protooncogenes, and modulate expression of proteins involved in cellular regulatory and apoptotic pathways. [14] [15] [16] [17] [24] [25] [26] [27] CMV has been associated with several specific human malignancies including carcinomas of the cervix, [28] [29] [30] [31] [32] prostate, [33] [34] [35] [36] and colon. [37] [38] [39] However, a number of conflicting reports have either failed to show evidence of an association with CMV or have questioned the significance of the presence of CMV in these particular tumors. [40] [41] [42] [43] [44] [45] There is relatively little information in the literature pertaining to CMV and brain neoplasms. Astrocytoma and glioblastoma cell lines have been shown to be at least somewhat permissive to CMV infection in vitro, 46 and a recent seroepidemiologic study has demonstrated that patients with glioblastoma multiforme were somewhat more likely to have antibodies to CMV than controls. 47 More direct evidence suggesting an association of CMV with gliomas has been provided in a recent study by Cobbs et al. 18 In this particular study, the CMVencoded IE1-72 protein was detected in the tumor cells of 27 of 27 gliomas of various grades by immunohistochemistry. A subset of these tumors also exhibited immunohistochemical positivity for Table 1 Results of CMV studies in brain tumors, normal brain, carcinomas, and sarcomas pp65 and CMV early proteins. The presence of CMV in these tumors was also demonstrated by in situ hybridization as well as by PCR. However, no CMV was identified in a control group of normal brain tissues, suggesting that the presence of CMV may play a possible role in glioma development. In contrast to the findings of this previous report, 18 in the present study, no immunohistochemical evidence of CMV protein expression was identified in any of the gliomas examined using monoclonal antibodies specific for CMV pp65 and early nuclear antigens. The absence of CMV protein expression in the brain tumors was also consistent with the observed in situ hybridization and PCR results, which likewise failed to demonstrate the presence of CMV mRNA and DNA. The reasons for this difference in observed positivity for CMV are unclear, as we used an in situ hybridization probe and PCR primers for specific CMV nucleic acids similar to those employed by Cobbs et al. 18 Minor differences in techniques and experimental conditions may be responsible for this discrepancy in results. Although immunohistochemical evaluation of CMV IE1-72 protein expression was not performed in the present study, we did utilize a monoclonal antibody which reacts with CMV pp65 protein, in addition to a cocktail of two monoclonal antibodies specific for CMV early nuclear antigens that has been previously demonstrated to be a highly sensitive and specific method of detecting CMV infection. [48] [49] [50] The findings of the current study are limited somewhat by the relatively small number of cases that were evaluated. In addition, it should be noted that this study focused primarily on gliomas, and did not specifically address neuronal, embryonal, or meningeal neoplasms. As such, an association between CMV and these particular types of central nervous system malignancies cannot be excluded.
Although a number of viruses have been shown to induce brain neoplasms in experimental animal systems, and viral genomic sequences have been detected in human brain tumors, a causal link between viral infections and nervous system malignancies has not been conclusively established. 51 The findings of the present study demonstrate no strong evidence for an association between CMV and various histologic types of brain neoplasms. The lack of localization of CMV by morphological and molecular analyses in these cases argues against a role for the virus in the etiology of brain tumors in humans. Further studies, which include larger numbers of cases and a broader spectrum of central nervous system neoplasms, are required to confirm the validity of these results.
